血栓与循环杂志：开放获取

抽象的

Clinical Management of Deep Vein Thrombosis

Abhilasha Singh

Venous thromboembolism (VTE) is assessed to happen in 350,000 – 600,000 people each year in the United States alone, of which more than 250,000 cases address first scenes of profound vein apoplexy (DVT). The administration of DVT has customarily been secured in a longstanding perspective on the infection as an "intense" condition including an underlying time of high danger of aspiratory embolism (PE), trailed by dynamically decreased danger of patient mischief over the long run. Subsequently, DVT treatments have been judged fundamentally on their capacity to forestall suggestive PE, early blood clot movement, and repetitive venous thromboembolism (VTE)